Definitions and incidence of cardiac syndrome X: review and analysis of clinical data

I. A. C. Vermeltfoort · P. G. H. M. Raijmakers · I. I. Riphagen · D. A. M. Odekerken · A. F. M. Kuijper · A. Zwijnenburg · G. J. J. Teule

Received: 16 July 2009 / Accepted: 7 April 2010 / Published online: 21 April 2010 © The Author(s) 2010. This article is published with open access at Springerlink.com

Abstract There is no consensus regarding the definition of cardiac syndrome X (CSX). We systematically reviewed recent literature using a standardized search strategy. We included 57 articles. A total of 47 studies mentioned a male/female distribution. A meta-analysis yielded a pooled proportion of females of 0.56 (n = 1,934 patients, with 95% confidence interval: 0.54–0.59). As much as 9 inclusion criteria and 43 exclusion criteria were found in the 57 articles. Applying these criteria to a population with normal coronary angiograms and treated in 1 year at a general hospital, the attributable CSX incidence varied between 3 and 11%. The many inclusion and exclusion criteria result in a wide range of definitions of CSX and these have large effects on the incidence. This shows the need for a generally accepted definition of CSX.

Keywords Cardiac syndrome X · Microvascular angina · Angina pectoris and normal coronary arteries

Introduction

The syndrome of angina pectoris with a normal coronary arteriogram, often termed cardiac syndrome X (CSX), is an important clinical entity [65]. About 20% of patients with anginal chest pain have normal coronary angiograms (CAG). Some physicians regard this as sufficient to diagnose CSX, the so-called broad diagnosis of CSX [65, 66]. However, the cause of CSX is not conclusively established and its definition is controversial. For example, a subgroup of these patients have objective signs of ischaemia, such as the classic downsloping ST-segment depression on exercise testing and/or a reversible defect detected by myocardial single-photon emission computed tomography (SPECT). Consequently, other authorities consider that CSX is discounted by a positive result from any diagnostic test for ischaemia, especially SPECT; and there is also the view that CSX might best be relabelled as one of several causes of microvascular dysfunction [37]. Furthermore, there are various exclusion criteria, such as hypertension and diabetes, that may or may not be used to discount the diagnosis of CSX. Finally, in overviews and textbooks it is often stated that (pre-menopausal) women are especially prone to developing cardiac syndrome X. In fact, some authors exclusively study female patient populations, but there is considerable variation in the proportion of women in other studies of CSX patients.

The present paper is a review to determine the gender and main definitions for CSX in the recent literature and also the effects of different definitions upon the attributable CSX incidence. To study this latter aspect we examined
and analysed the CAG data for a population of patients treated in a general hospital in the Netherlands.

Methods

CSX definitions

The PubMed database was used to identify papers in which criteria and definitions for CSX are described. Our search consisted of ‘(cardiac syndrome x[tia]) NOT (case reports[pt] OR comment[pt] OR review[pt])’, with limits set to English language, humans, and publication date between June 2003 and July 2008. We limited our search strategy to cardiac syndrome X and excluded metabolic syndrome X and tako-tsubo cardiomyopathy [6, 24, 42]. This search yielded 112 references. Conference abstracts, pediatric papers, and ‘epublications ahead of print’ were excluded. Of 83 articles the full text was retrieved for further analysis. Articles were independently surveyed by two authors (IV and GT) and reviewed with regard to their used definitions of CSX. The survey left 57 studies for this review.

Impact of CSX definition upon CSX incidence

All the CAGs made in 2003 in a general hospital (Spaarne Hospital Hoofddorp, The Netherlands) were collected. An extensive search was made to obtain the clinical history, physical examination, routine laboratory tests, and echocardiography results for all patients with CAGs stated to be completely normal. All CAGs were independently evaluated by two experienced observers (AK and DO).

Only patients with original angiograms and sufficient clinical data were included in the present study.

Results

CSX definitions

The 57 papers selected for determining the main definitions of CSX covered a total of 2,375 patients. A normal coronary angiogram was used in the majority of the studies. However, in a few studies minimal coronary artery disease, like atheromatous plaque without critical obstructions, is included as “normal coronary angiogram” [18, 22, 56]. A few studies state minimal coronary artery disease in the exclusion criteria [1]. But in the majority of the studies there was no statement regarding minimal artery disease. Only few studies specified the interpretation of the normal coronary angiograms, like revision of the CAG films, blinded observation, or interpretation by more reviewers.

Table 1 lists the nine CSX definitions, and hence inclusion criteria, obtained from our review of the 57 studies.

In more detail:

- Out of the 57 studies 42 required positive exercise electrocardiograms for the diagnosis of CSX. The general criterion, when given, for a positive exercise stress test result was uniform ST depression ≥1 mm. Only one study considered stress-induced angina without significant ST depression to be positive for ischaemia [15].
- As much as 11 studies regarded positive myocardial perfusion images to be good alternatives to a positive result from exercise testing.
- As much as 18 studies considered effort-induced angina pectoris as an inclusion criterion.
- Four studies defined CSX simply as angina pectoris and normal CAG, the so-called broad diagnosis of CSX.

Table 1 Inclusion criteria for CSX

| Inclusion criteria for CSX | Number of studies |
|---------------------------|-------------------|
| Angina pectoris           | 18                |
| Positive exercise stress test |                  |
| Normal coronary arteries  |                   |
| Effort induced angina pectoris |              |
| Positive exercise stress test |               |
| Normal coronary arteries  |                   |
| Angina pectoris           | 11                |
| Positive exercise stress test OR positive SPECT |   |
| Normal coronary arteries  |                   |
| Angina pectoris           | 4                 |
| Normal coronary arteries  |                   |
| Angina pectoris           | 4                 |
| Positive exercise stress test AND positive SPECT |   |
| Normal coronary arteries  |                   |
| Angina pectoris           | 1                 |
| Positive exercise stress test |               |
| No significant CAD on CAG |                   |
| Effort induced AP         | 1                 |
| Positive exercise stress test |               |
| Normal coronary arteries AND prolonged coronary flow on CAG | |
| Angina pectoris           | 1                 |
| Positive exercise stress test |               |
| Normal coronary arteries AND reduced LVEF on echo |   |
| Angina pectoris           | 1                 |
| Positive SPECT            |                   |
| Normal coronary arteries  |                   |

CSX cardiac syndrome X; AP angina pectoris; CAG coronary angiogram; SPECT single photon emission tomography; LVEF left ventricular ejection fraction
Table 2 lists no less than 43 exclusion criteria for CSX. The most frequently used exclusion criteria are valvular heart disease, diabetes mellitus, left ventricular hypertrophy, hypertension, and cardiomyopathy.

In overviews and textbooks it is often stated that (pre-menopausal) women are especially prone to develop cardiac syndrome X.

In Table 3 data of individual studies are presented.

| Table 2 Exclusion criteria included studies  |
|--------------------------------------------|
| Exclusion criteria used in the studies for present review | N studies of 57 total |
|---------------------------------------------|----------------------|
| Valvular heart disease | 33 |
| Diabetes mellitus | 32 |
| Left ventricular hypertrophy | 26 |
| Hypertension | 24 |
| Cardiomyopathy (non specified) | 23 |
| Renal failure | 22 |
| History of myocardial infarction | 15 |
| LV dysfunction | 14 |
| Coronary spasm | 13 |
| Hepatic dysfunction | 12 |
| Arrhythmias | 9 |
| Inflammatory disease | 9 |
| Dyslipidaemia | 8 |
| Left bundle branch block | 8 |
| Cardiac disease (non specified) | 7 |
| Gastro Intestinal disorder | 7 |
| Systemic disease (non specified) | 6 |
| Smoking | 6 |
| Thyroid dysfunction | 5 |
| Obesitas | 5 |
| Non-cardiac chest pain | 5 |
| Conduction disorder (incl LBTB) | 5 (13) |
| Hypertrophic CMP (total CMP) | 5 (23) |
| Congestive CMP (total CMP) | 5 (23) |
| Dilated CMP (CMP total) | 4 (23) |
| Alcoholism | 4 |
| Metabolic syndrome | 4 |
| Dysphagia/oesophagitis | 3 |
| Malignancy | 3 |
| LVEF < 40% | 2 |
| Psychiatric illness | 2 |
| Auto immune disease | 2 |
| Estrogen replacement therapy | 2 |
| PTCA/CABG in history | 2 |
| Ectasia on CAG | 2 |
| Briding on CAG | 2 |
| Claudicatio intermittens | 2 |
| Heart failure (non specified) (total) | 1 (17) |
| Myocarditis | 1 |
| Congenital heart disease | 1 |
| Aortic wall diseases | 1 |
| Anaemia | 1 |
| Thrombocytopenia | 1 |

| Table 3 Included studies of CSX patients  |
|----------------------------------------|
| Included study of CSX patients | Year | n | Female (%) | Mean age (Y) |
|-----------------------------------|------|---|------------|-------------|
| Lee [41] | 2008 | 21 | 81 | 55 |
| Timurkaynak [61] | 2008 | 79 | 54 | 50 |
| Cemin [11] | 2008 | 11 | 100 | 59 |
| Zorc-Pleskovic [66] | 2008 | 31 | 100 | 55 |
| Lanza [38] | 2008 | 18 | 61 | 58 |
| Altun [2] | 2007 | 9 | 77 | 49 |
| Cotrim [12] | 2008 | 91 | 48 | 51 |
| Asbury [5] | 2008 | 64 | 100 | 58 |
| Demir [18] | 2008 | 17 | 41 | 57 |
| Grabczewska [23] | 2007 | 53 | 57 | 55 |
| Li [44] | 2007 | 36 | 100 | NA |
| Okyar [48] | 2007 | 32 | 66 | 53 |
| Dabek [15] | 2007 | 34 | 65 | 57 |
| Yildiz [64] | 2007 | 10 | 79 | 49 |
| Kayikcioglu [33] | 2007 | 30 | 60 | 46 |
| Mao [45] | 2007 | 51 | 78 | 21 |
| Dabek [14] | 2007 | 36 | 65 | 57 |
| Vermelldfoort [63] | 2007 | 20 | 75 | 55 |
| Galiuto [21] | 2007 | 17 | 53 | 55 |
| Alroy [1] | 2007 | 42 | 100 | 52 |
| Huang [29] | 2007 | 12 | 60 | 63 |
| Guzik [28] | 2007 | 43 | 65 | 44 |
| Gurb [26] | 2007 | 23 | 70 | 49 |
| Gurb [27] | 2007 | 23 | NA | NA |
| Sgueglia [59] | 2007 | 30 | 73 | 61 |
| Russell [55] | 2007 | 24 | 89 | 54 |
| Sen [56] | 2007 | 203 | 58 | 53 |
| Shmilovich [60] | 2007 | 17 | 71 | 58 |
| de Vries [17] | 2006 | 42 | 26 | 58 |
| Nam [47] | 2006 | 52 | NA | NA |
| Eskandarian [19] | 2006 | 40 | 73 | 46 |
| Cay [10] | 2006 | 126 | 62 | 53 |
| JadHAV [30] | 2006 | 52 | 100 | 56 |
| Czepczynski [13] | 2006 | 68 | 63 | 45 |
| Leu [43] | 2006 | 92 | 21 | 64 |
| Lanza [40] | 2005 | 10 | 59 | 70 |
| Cay [9] | 2005 | 80 | 52 | 51 |
| On [49] | 2005 | 36 | 53 | 36 |
| Guo [25] | 2005 | 22 | 68 | 48 |
| Masci [46] | 2005 | 41 | NA | 53 |
| Senen [57] | 2005 | 21 | 48 | 56 |
| Pasqui [51] | 2005 | 30 | 60 | 54 |
| Sestito [58] | 2005 | 30 | 73 | 60 |
In 53 out of the total of 57 included studies the female/male distribution of the study population was mentioned. Six studies were focussed upon female patients with CSX. These studies were excluded for the pooling of the proportion of women in the study populations. Ultimately 47 studies with a total of 1,934 patients could be used for the meta-analysis.

The proportion of women in the 47 studies of CSX patients varied considerably ranging from 0.21 to 1.0, with a pooled estimate of 0.56 (95% confidence interval: 0.54–0.59), see also Fig. 1. Hence, there is a significantly higher proportion of woman compared to males in the group of patients with CSX.

CSX incidence

As much as 567 CAGs were performed in 1 year at a general hospital. Figure 2 is a flowchart showing how we analysed the available information. The main stages are:

- Original CAGs or clinical data could not be found for eight patients, leaving 559 cases for analysis.
- Out of the available 559 CAGs 78 (14%) were considered as absolutely normal.
- Excluding 13 cases with no angina pectoris as indication for CAG, and another 5 with an acute coronary syndrome, resulted in an incidence of 60 (11%) CSX patients according to the broad diagnosis of CSX (angina pectoris and normal coronary arteries) [17, 23, 54, 65, 66].
- Another 15 cases were excluded owing to the lack of exercise stress tests or myocardial perfusion imaging preceding the CAG.

**Discussion**

CSX definitions and incidences

The present review of recent archival literature demonstrates that there is a wide range of definitions of CSX. This wide range of definitions has a large effect on the attributable incidence of CSX, as has been shown by an analysis of all available CAGs and other clinical data for a population of patients treated in 1 year at a general hospital.
Generally, it is stated that patients with chest pain and normal coronary arteriogram may represent 10–20% of those undergoing coronary arteriography because of clinical suspicion of angina [65]. This is in broad agreement with our analysis results that 11% of patients had a normal CAG. The rather low incidence of normal CAG can be the result of the use of rather strict criteria for a normal CAG including a consensus reading by two independent readers of the CAG’s.

It is generally accepted (e.g. in authoritative textbooks) that the majority of the CSX patients are women [32, 65]. Some authors have even suggested that CSX is a women’s disease. However, our review has found a pooled relative female frequency of 56% in a population of more than 1,900 CSX patients. Thus, our data do not support the assumption that CSX is a women’s disease, since 44% of the population was male. Potential pathophysiological explanations, such as estrogen depletion, which are based upon the female gender, apply only to a part of the CSX patients [31].

Inclusion and exclusion criteria

The literature survey showed that the inclusion and exclusion criteria varied. This was especially the case for the exclusion criteria.

The definition of ‘normal coronary arteries’ was particularly unclear. Most studies did not define a normal CAG, and some included patients with coronary artery disease (CAD) ranging from minimal to stenoses up to 50% of luminal diameter. Obviously, normal coronary arteries are the cornerstone of the diagnosis of CSX. Hence, there should be no doubt regarding the use of this inclusion criterion for studies of CSX patients. Future studies of CSX patients should make a clear description regarding the evaluation and results of the CAG studies of the coronary artery anatomy.

The so-called broad diagnosis for CSX, a combination of 2 inclusion criteria (angina pectoris and normal coronary arteries) was used only in four studies (7%).

Most studies used a combination of three inclusion criteria, namely (effort induced) angina pectoris, positive exercise test result, and a normal CAG. This definition was used in 46 out of 57 studies (81%). The use of this additional inclusion criterion resulted in a decrease of the incidence of CSX to 7% in our population. The definition of a positive exercise stress test appears to be more standardized than the definition of a normal CAG. Most publications used a ST depression ≥1 mm as a positive exercise stress test: only 12 out of the 57 studies did not define a positive stress test.

The use of specific exclusion criteria ranged from 2 to 58% of the selected studies of CSX patients, often depending on the main objectives of the studies, for example the use of thrombocytopenia as an exclusion criterion in a study investigating the mean platelet volume [9].

The most frequently mentioned exclusion criteria are valvular heart disease, diabetes mellitus, left ventricular hypertrophy, hypertension, and cardiomyopathy. Endothelial dysfunction has been assessed both in patients with diabetes mellitus and hypertension with normal CAG, and in patients with CSX without diabetes or hypertension. Interestingly, coronary flow reserve may be reversible in specific patient groups, e.g. in patients with hypertension after anti-hypertensive therapy [52]. However, we note that most international studies consider diabetes mellitus and hypertension to be exclusion criteria for CSX, thereby considering these patients as a separate group.

The existence of such a long list of exclusion criteria in the selection process of CSX patients illustrates the lack of agreement between the different research groups regarding
the origins of this syndrome. Besides the use of a standard and fixed combination of inclusion criteria future studies should apply a standard combination of exclusion criteria.

In a recent editorial, Camici proposed the following exclusion criteria in order to obtain a more homogeneous set of cardiac syndrome X patients: absence of left bundle branch block; absence of even minimal irregularities on the angiogram; no evidence of diabetes mellitus, arterial hypertension, hyperlipidaemia, valve disease, epican-dial arterial spasm, and cardiomyopathy [7].

In our selection of CSX patients we decided to include only patients with completely normal coronary angiograms, effort-induced angina pectoris, positive exercise stress test and/or positive SPECT study. Furthermore, we decided to add arrhythmias, left ventricular hypertrophy, myocardial infarction in the medical history, and myocardial bridging to the exclusion criteria proposed by Camici. These inclusion and exclusion criteria resulted in an attributable CSX incidence of only 3%.

Conclusions

The wide range of definitions of CSX in recent literature and the variations in inclusion and exclusion criteria, particularly the latter, make interpretation of the results of individual studies difficult. This shows the need for a generally accepted definition of CSX.

Acknowledgments We thank Dr. R.J.H. Wanhill for his critical review and editing of the manuscript.

Conflict of interest statement None.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Alroy S, Preis M, Barzilai M et al (2007) Endothelial cell dysfunction in women with cardiac syndrome X and MTHFR C677T mutation. Isr Med Assoc J 9:321–325
2. Altun A, Turgut N, Tatli E et al (2007) Sympathetic skin response and RR interval variation in patients with cardiac syndrome X. Angiology 58:747–750
3. Altun A, Ugur-Altun B, Tatli E (2004) Decreased serum osteoprotegerin levels in patients with cardiac syndrome X. J Endocrinol Invest 27:839–843
4. Ashbury EA, Creed F, Collins P (2004) Distinct psychosocial differences between women with coronary heart disease and cardiac syndrome X. Eur Heart J 25:1695–1701
5. Ashbury EA, Slattery C, Grant A et al (2008) Cardiac rehabilitation for the treatment of women with chest pain and normal coronary arteries. Menopause 15:454–460
6. Athanasiadis A, Vogelsberg H, Hauer B et al (2006) Transient left ventricular dysfunction with apical ballooning (tako-tsubo cardiomyopathy) in Germany. Clin Res Cardiol 95:321–328
7. Camici PG (2007) Is the chest pain in cardiac syndrome X due to subendocardial ischaemia? Eur Heart J 28:1539–1540
8. Cavusoglu Y, Entok E, Timuralp B et al (2005) Regional distribution and extent of perfusion abnormalities, and the lung to heart uptake ratios during exercise thallium-201 SPECT imaging in patients with cardiac syndrome X. Can J Cardiol 21:57–62
9. Cay S, Biyikoglu F, Cihan G et al (2005) Mean platelet volume in the patients with cardiac syndrome X. J Thromb Thrombolysis 20:175–178
10. Cay S, Guray U, Korkmaz S (2006) Increased aortic pulse and fractional pulse pressures in patients with cardiac syndrome X. Blood Press 15:179–184
11. Cemin R, Erlacher A, Fattor B et al (2008) Reduced coronary flow reserve and parasympathetic dysfunction in patients with cardiovascular syndrome X. Coron Artery Dis 19:1–7
12. Cotrim C, Almeida AG, Arragaeta M (2008) Exercise-induced intra-ventricular gradients as a frequent potential cause of myocardial ischaemia in cardiac syndrome X patients. Cardiovasc Ultrasound 6:3
13. Czepczynski R, Smolarek I, Rogacka D et al (2006) Myocardial perfusion SPECT with dipipyridamole stress test in cardiac syndrome X. Nuklearmedizin 45:111–114
14. Dabek J, Kulach A, Wilczok T et al (2007) Transcriptional activity of genes encoding interferon gamma (IFNgamma) and its receptor assessed in peripheral blood mononuclear cells in patients with cardiac syndrome X. Inflammation 30:125–129
15. Dabek J, Wilczok T, Gasior Z et al (2007) Gene expression of kinin receptors B1 and B2 in PBMC from patients with cardiac syndrome X. Scand Cardiovasc J 41:391–396
16. De Candia E, Lanza GA, Romagnoli E et al (2005) Abnormal pH-sensing of platelet Na+/H+ exchanger in patients with cardiac syndrome X. Int J Cardiol 100:371–376
17. de Vries J, De Jongste MJ, Jessurun GA et al (2006) Myocardial perfusion quantification in patients suspected of cardiac syndrome X with positive and negative exercise testing: a [13N]ammonia positron emission tomography study. Nucl Med Commun 27:791–794
18. Demir H, Kahrman G, Igson S et al (2008) Evaluation of post-stress left ventricular dysfunction and its relationship with perfusion abnormalities using gated SPECT in patients with cardiac syndrome X. J Nucl Med Commun 29:208–214
19. Eskandarian R, Malek M, Mousavi SH et al (2006) Association of Helicobacter pylori infection with cardiac syndrome X. Singapore Med J 47:704–706
20. Fabian E, Varga A, Picano E et al (2004) Effect of simvastatin on endothelial function in cardiac syndrome X patients. Am J Cardiol 94:652–655
21. Gal벞o L, Sestito A, Barchetta S et al (2007) Noninvasive evaluation of flow reserve in the left anterior descending coronary artery in patients with cardiac syndrome X. Am J Cardiol 99:1378–1383
22. Gorgulu S, Uslu N, Eren M et al (2003) Aortic stiffness in patients with cardiac syndrome X. Acta Cardiol 58:507–511
23. Grabczewska Z, Thews M, Goralczyk K et al (2007) Endothelial function in patients with chest pain and normal coronary angiograms. Kardiol Pol 65:1199–1206
24. Grawe H, Katoh M, Kuhl HP (2006) Stress cardiomyopathy mimicking acute coronary syndrome: case presentation and review of the literature. Clin Res Cardiol 95:179–185
25. Guo H, Lee JD, Guo M et al (2005) Status of intracellular and extracellular magnesium concentration in patients with cardiac syndrome X. Acta Cardiol 60:259–263
26. Gur M, Yildiz A, Demirbag R et al (2007) Paraoxonase and arylesterase activities in patients with cardiac syndrome X, and
their relationship with oxidative stress markers. Coron Artery Dis
18:89–95
27. Gur M, Yildiz A, Demirbag R et al (2007) Increased lymphocyte
deoxyribonucleic acid damage in patients with cardiac syndrome
X. Mutat Res 617:8–15
28. Gazik P, Rogacka D, Trachalski J et al (2007) Comparison of the
exercise treadmill test and 24-hour ECG Holter monitoring in
patients with syndrome X or coronary atherosclerosis. Kardiol
Pol 65:262–269
29. Huang PH, Chen YH, Chen YL et al (2007) Vascular endothelial
function and circulating endothelial progenitor cells in patients
with cardiac syndrome X. Heart 93:1064–1070
30. JadHAV ST, Ferrell WR, Petrie JR et al (2006) Microvascular
function, metabolic syndrome, and novel risk factor status in
women with cardiac syndrome X. Am J Cardiol 97:1727–1731
31. Kaski JC (2006) Cardiac syndrome X in women: the role of
oestrogen deficiency. Heart 92(Suppl 3):iii5–iii9
32. Kaski JC (2002) Overview of gender aspects of cardiac syndrome
X. Cardiovasc Res 53:620–626
33. Kayikcioglu M, Saygi S, Azarsiz E et al (2007) Serum proa-
oxonase 1 activity and oxidative markers of LDL in patients with
cardiac syndrome X. Acta Cardiol 62:245–249
34. Kidawa M, Krzeminska-Pakula M, Peruga JZ et al (2003) Car-
diologial syndrome X Non-invasive assessment of endothelial
function and arterial compliance. Kardiol Pol 59:385–396
35. Kolasińska-Kloch W, Lesniak W, Leszcynska-Golabek I et al
(2004) Exercise tolerance and hyperinsulinemia in cardiac syn-
drome X. Folia Med Cracov 45:13–23
36. Kolasińska-Kloch W, Furgala A, Królczyk G et al (2004) Cardiac
syndrome X-autonomic system disorders. Folia Med Cracov
45:19–29
37. Lanza GA (2007) Cardiac syndrome X: a critical overview and
future perspectives. Heart 93:159–166
38. Lanza GA, Buffon A, Sestito A et al (2007) Relation between stress-induced myocardial perfusion defects on cardio-
vascular magnetic resonance and coronary microvascular dys-
function in patients with cardiac syndrome X. J Am Coll Cardiol
51:466–472
39. Lanza GA, Sestito A, Cammarota G et al (2004) Assessment of
systemic inflammation and infective pathogen burden in patients
with cardiac syndrome X. Am J Cardiol 94:40–44
40. Lanza GA, Sestito A, Sgueglia GA et al (2005) Effect of spinal
cord stimulation on spontaneous and stress-induced angina and
"ischemia-like" ST-segment depression in patients with cardiac syndrome X. Eur Heart J 26:983–989
41. Lee BK, Durairaj A, Mehra A et al (2008) Microcirculatory
dysfunction in cardiac syndrome X: role of abnormal blood
rheology. Microcirculation 15:451–459
42. Leichman JG, Lavis VR, Aguilar D et al (2006) The metabolic
syndrome and the heart—a considered opinion. Clin Res Cardiol
95(Suppl 1):i134–i141
43. Leu HB, Lin CP, Lin WT et al (2006) Circulating mononuclear
superoxide production and inflammatory markers in long-term
prognosis in patients with cardiac syndrome X. Free Radic Biol
Med 40:983–991
44. Li JJ, Zhu CG, Nan JL et al (2007) Elevated circulating inflam-
matory markers in female patients with cardiac syndrome X.
Cytokine 40:172–176
45. Mao JY, Ge YB, Wang HH et al (2007) Summary of 32 patients
with cardiac syndrome X treated by TCM therapy of regulating qi
relieving chest stuffiness and promoting blood circulation. Chin J
Integr Med 13:17–21
46. Masci PG, Laclaustra M, Lara JG et al (2005) Brachial artery
flow-mediated dilation and myocardial perfusion in patients with
cardiac syndrome X. Am J Cardiol 95:1478–1480
47. Nam CW, Kim KS, Lee YS et al (2006) The incidence of gastro-
esophageal disease for the patients with typical chest pain and a
normal coronary angiogram. Korean J Intern Med 21:94–96
48. Okay K, Cengel A, Sahinarslan A et al (2007) Plasma asym-
metric dimethylarginine and L-arginine levels in patients with
cardiac syndrome X. Coron Artery Dis 18:539–544
49. On YK, Park R, Hyon MS et al (2005) Are low total serum
antioxidant status and elevated levels of C-reactive protein and
monocyte chemotactic protein-1 associated with cardiac syn-
drome X? Circ J 69:1212–1217
50. Osamichi S, Kouji K, Yoshimaro I et al (2004) Myocardial glu-
cose metabolism assessed by positron emission tomography and
the histopathologic findings of microvessels in syndrome X. Circ
J 68:220–226
51. Pasqui AL, Puccetti L, Di Renzo M et al (2005) Structural and
functional abnormality of systemic microvessels in cardiac syn-
drome X. Nutr Metab Cardiovasc Dis 15:56–64
52. Petkow Dimitrow P, Krzanowski M, Nizankowski R et al (2000)
Effect of verapamil on systolic and diastolic coronary blood flow
velocity in asymptomatic and mildly symptomatic patients with
hypertrophic cardiomyopathy. Heart 83:262–266
53. Pizzi C, Manfrini O, Fontana F et al (2004) Angiotensin-con-
verting enzyme inhibitors and 3-hydroxy-3-methylglutaryl
coenzyme A reductase in cardiac Syndrome X: role of superoxide
dismutase activity. Circulation 109:53–58
54. Qian JY, Ge JB, Fan B et al (2004) Identification of syndrome X
using intravascular ultrasound imaging and Doppler flow map-
ing. Chin Med J (Engl) 117:521–527
55. Russell SJ, Di Stefano EM, Naffiati MT et al (2007) The effects of
the angiotensin II receptor (type I) antagonist irbesartan in
patients with cardiac syndrome X. Heart 93:253–254
56. Sen N, Tavil Y, Yazici HU et al (2007) Coronary blood flow in
patients with cardiac syndrome X. Coron Artery Dis 18:45–48
57. Senen K, Ileri M, Alper A et al (2005) Increased levels of soluble
adhesion molecules E-selectin and P-selectin in patients with
cardiac syndrome X. Angiology 56:273–277
58. Sestito A, Maccallini A, Sgueglia GA et al (2005) Platelet reac-
tivity in response to mental stress in syndrome X and in stable or
uncertain coronary artery disease. Thromb Res 116:25–31
59. Sgueglia GA, Sestito A, Spinelli A et al (2007) Long-term fol-
low-up of patients with cardiac syndrome X treated by spinal
cord stimulation. Heart 93:591–597
60. Shmilovich H, Deutsch V, Roth A et al (2007) Circulating
endothelial progenitor cells in patients with cardiac syndrome X.
Heart 93:1071–1076
61. Timurkaynak T, Balcioglu S, Arslan U et al (2008) Plasma
homocysteine level in cardiac syndrome X and its relation with
duke treadmill score. Saudi Med J 29:364–367
62. Valeriani M, Sestito A, Le Pera D et al (2005) Abnormal cortical
pain processing in patients with cardiac syndrome X. Eur Heart J
26:975–982
63. Vemeltfoort IA, Bondarenko O, Raijmakers PG et al (2007) Is
subendocardial ischaemia present in patients with chest pain and
normal coronary angiograms? A cardiovascular MR study. Eur
Heart J 28:1554–1558
64. Yildiz M, Altun A, Ozbuy G (2007) Assessment of arterial dis-
tensibility in patients with cardiac syndrome X. Angiology
58:458–462
65. Zipes DP, Libby P, Bonow RO et al (2008) Braunwald’s heart
disease: a textbook of cardiovascular medicine, 8 edn. Saunders-
Elsevier, Philadelphia
66. Zorc-Leskovsek R, Vrapsip-Porenta O, Zorc M et al (2008)
Inflammatory changes in small blood vessels in the endomyo-
cardium of cardiac syndrome X in female patients with increased
C-reactive protein. Folia Biol (Praha) 54:30–32